Jaguar Health Inc (JAGX)

0.41
NASDAQ : Health Care
Prev Close 0.39
Day Low/High 0.39 / 0.42
52 Wk Low/High 0.34 / 1.53
Avg Volume 664.20K
Exchange NASDAQ
Shares Outstanding 67.70M
Market Cap 26.40M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jaguar Health Announces Proposed Public Offering Of Common Stock

Jaguar Health Announces Proposed Public Offering Of Common Stock

Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human...

Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire Of Experienced HIV & GI Drug Sales Reps In Key U.S. Markets

Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire Of Experienced HIV & GI Drug Sales Reps In Key U.S. Markets

Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and...

New Survey Ranks Diarrhea As Number One Gastrointestinal Complaint Of HIV/AIDS Patients

New Survey Ranks Diarrhea As Number One Gastrointestinal Complaint Of HIV/AIDS Patients

Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of...

Jaguar Health Company Name Now Updated On Nasdaq.com Post-Merger

Jaguar Health Company Name Now Updated On Nasdaq.com Post-Merger

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and...

Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation For Mytesi (crofelemer) For Treatment Of Short Bowel Syndrome

Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation For Mytesi (crofelemer) For Treatment Of Short Bowel Syndrome

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and...

The Merger Of Jaguar Animal Health And Napo Pharmaceuticals Is Effective

The Merger Of Jaguar Animal Health And Napo Pharmaceuticals Is Effective

The merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc.

Stockholders Of Jaguar Animal Health And Napo Pharmaceuticals Vote To Approve Merger

Stockholders Of Jaguar Animal Health And Napo Pharmaceuticals Vote To Approve Merger

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar) and Napo Pharmaceuticals, Inc.

New Data Shows Dramatic Reduction In Chronic Diarrhea Episodes With Crofelemer (Mytesi) Treatment

New Data Shows Dramatic Reduction In Chronic Diarrhea Episodes With Crofelemer (Mytesi) Treatment

Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and Jaguar Animal Health, Inc.

Jaguar Neonorm Foal Study Accepted For Publication In Veterinary Journal

Jaguar Neonorm Foal Study Accepted For Publication In Veterinary Journal

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Animal Health To Hold Special Meeting Of Stockholders July 27, 2017 To Vote Upon The Consummation Of Its Proposed Merger With Napo Pharmaceuticals, Inc.

Jaguar Animal Health To Hold Special Meeting Of Stockholders July 27, 2017 To Vote Upon The Consummation Of Its Proposed Merger With Napo Pharmaceuticals, Inc.

As previously announced, Jaguar Animal Health, Inc. (NASDAQ:JAGX) (Jaguar) will hold a special meeting of its stockholders on Thursday, July 27, 2017, to consider and vote on a number of proposals recommended by Jaguar's...

Napo Pharmaceuticals To Present New Crofelemer (Mytesi) Data At International Aids Society Conference On HIV Science

Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and Jaguar Animal Health, Inc.

Jaguar Animal Health's Neonorm Calf Obtains OMRI Listing And Can Now Be Used In Production Of Certified Organic Dairy And Beef Cattle

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Animal Health Launches Commercial Website For Neonorm Foal & Neonorm Calf

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Animal Health And Napo Pharmaceuticals Announce Filing Of Two Orphan Drug Designation Applications With FDA For Mytesi For Serious Unmet Medical Needs

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Lisa Conte, CEO Of Jaguar Animal Health And Napo Pharmaceuticals, To Present At The Southern California Investment Forum May 31, 2017 In Los Angeles

Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Napo Pharmaceuticals' New Mytesi Video Calls Attention To The Continuing Widespread Problem Of Diarrhea In People Living With HIV/AIDS

Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, which launched Mytesi ® in...

Jaguar Animal Health And Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi To Chair Scientific Advisory Board

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Signs Distribution Agreement For Japan For Neonorm Foal & Neonorm Calf

Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar And Napo Issue Commercial Updates

Jaguar Animal Health, Inc. (NASDAQ:JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

The animal health company combines with its former owner in a reverse merger.

Jaguar Animal Health Stock Rises on Napo Pharma Merger

Jaguar Animal Health Stock Rises on Napo Pharma Merger

Jaguar Animal Health (JAGX) stock was surging by 20% to $1.14 on Friday morning

Jaguar Animal Health Stock Skyrocketing on Napo Pharma Merger

Jaguar Animal Health Stock Skyrocketing on Napo Pharma Merger

Jaguar Animal Health and Napo Pharmaceuticals have signed a merger agreement.

Jaguar Animal Health And Napo Pharmaceuticals Enter Definitive Merger Agreement

Napo Pharmaceuticals, Inc. ("Napo"), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and Jaguar Animal Health, Inc.

Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar's Drug Product Candidate For Equine Gastric Ulcer Syndrome

Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Animal Health Seeks MUMS Designation For Canalevia For Exercise-Induced Diarrhea In Dogs

Jaguar Animal Health, Inc. (NASDAQ:JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...

Jaguar Animal Health To Participate In 29th Annual ROTH Conference The Week Of March 13th In Orange County, California

Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value...